johnson-&-johnson
(3)
Jennifer Bergheiser
Jennifer Bergheiser is the Chief Business Officer of eGenesis, the Cambridge biotech turning gene-edited pig organs into a real answer to the transplant waitlist. She runs corporate strategy and all portfolio and commercial development, drawing on more than two decades across big pharma, venture capital, and consulting. Her resume runs from screening deals at Domain Associates to steering the blockbuster autoimmune drug Stelara at Centocor/Johnson & Johnson. At eGenesis she helps commercialize one of medicine's boldest bets: organs grown in pigs, edited dozens of times over, transplanted into living humans.
Sungwoo Min
Sungwoo Min is the founder and CEO of Nventric, Inc., an Arcadia, California medical device company that designs, develops, and contract-manufactures vascular devices for the neurovascular, electrophysiology, and coronary markets. A Stanford-trained mechanical engineer who cut his teeth on R&D and marketing at Abbott Vascular and later led R&D programs at Johnson & Johnson, he started Nventric in 2019 to build the kind of life-saving catheters, stents, and thrombectomy systems he used to ship at the giants - this time end to end, ISO 13485 certified, with operations in the US and South Korea. He is a named inventor on multiple US patents for mechanical thrombectomy devices.
Mathai Mammen
Mathai Mammen is the Chairman, CEO and President of Parabilis Medicines (formerly FogPharma), a Cambridge biotech going after cancer targets long written off as undruggable. A trained physician-chemist who co-founded Theravance out of grad school and later ran R&D at Merck and Johnson & Johnson, he has had a hand in the discovery or development of roughly 19 approved medicines. At Parabilis he is betting on Helicon peptides - engineered molecules that slip inside cells to hit protein-protein interfaces small molecules and antibodies cannot reach.